Bayer, Regeneron Begin China Phase III Trial Of ‘Wet’ AMD Drug
This article was originally published in PharmAsia News
Executive Summary
Two U.S. drug makers are joining in a Phase III clinical trial in China of their age-related macular degeneration drug, Eylea (aflibercept).